Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting [Yahoo! Finance]
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Citigroup Inc. from $70.00 to $74.00. They now have a "buy" rating on the stock.
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) [Yahoo! Finance]